Online inquiry

IVTScrip™ mRNA-Anti-GCGR, REGN-1193(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ13836MR)

This product GTTS-WQ13836MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 1 & 5-Methyl-CTP & Pseudo-UTP. It ecodes the monoclonal antibody that targets GCGR gene. The antibody can be applied in Type 2 diabetes (T2 DM) research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP & Pseudo-UTP
5' Cap Cap 1
Species Homo sapiens
RefSeq NM_000160.5
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 2642
UniProt ID P47871
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-GCGR, REGN-1193(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) (GTTS-WQ13836MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ3940MR IVTScrip™ mRNA-Anti-CTLA4, BCD-145(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) mRNA BCD-145
GTTS-WQ5636MR IVTScrip™ mRNA-Anti-TNF, CDP870(Cap 0, Pseudo-UTP, 30 nt-poly(A)) mRNA CDP870
GTTS-WQ15765MR IVTScrip™ mRNA-Anti-CA9, WX-G250(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA WX-G250
GTTS-WQ15082MR IVTScrip™ mRNA-Anti-KDR, SSS-23(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) mRNA SSS-23
GTTS-WQ2974MR IVTScrip™ mRNA-Anti-IL33, ANB020(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA ANB020
GTTS-WQ10291MR IVTScrip™ mRNA-Anti-PCSK9, LGT209(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA LGT209
GTTS-WQ9957MR IVTScrip™ mRNA-Anti-hly, KBSA301(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA KBSA301
GTTS-WQ80MR IVTScrip™ mRNA-Anti-H1-0, (131)I-chTNT-1/B(Cap 0, Pseudo-UTP, 30 nt-poly(A)) mRNA (131)I-chTNT-1/B
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW